Western Pharma Giants Paid Millions to Russian Distributors Linked to Fraud, Whistleblower Report Says
Four major Western drugmakers allegedly paid unusually high bonuses to Russian middlemen supplying cancer drugs to state hospitals, according to whistleblower documents filed with U.S. regulators. The companies either declined to comment or did not respond.
Pharmaceutical companies Merck, Eli Lilly, Novartis and AstraZeneca allegedly paid tens of millions of dollars in unusually high bonuses to Russian distributors that supplied cancer drugs to state hospitals, according to whistleblower documents submitted to U.S. financial regulators. The payments are alleged to have helped fund a corruption scheme that kept drug prices high and restricted competition in Russia's public healthcare system. The findings were published Monday in a joint investigation by the International Consortium of Investigative Journalists (ICIJ), the exiled Russian outlet Proekt and the Swiss publication Republik.
Bonuses and rebates
The documents claim the companies gave Russian distributors "excessive" sales bonuses and rebates of 15% to 35%, while the international average rarely exceeds 10%.
Specific examples
According to the report, Merck's distributor R-Pharm won $360 million in state contracts for the cancer drug Keytruda between 2020 and 2022, taking 2,400 of nearly 5,000 bids. Procurement data reportedly showed 96% of bids had no competitors, letting the company of sanctioned oligarch Alexei Repik keep a virtual monopoly. R-Pharm CEO Vasily Ignatyev denied any involvement in improper payments or non-competitive practices, saying the commercial rebates were legitimate and the state auction procedures transparent.
Eli Lilly allegedly budgeted a 34% bonus for sales of its cancer drug Cyramza in 2022. The year before, Moscow's health department awarded more than $5 million in Cyramza contracts to distributor Pharmstandard, the sole bidder for most of them.
AstraZeneca's drug Tagrisso was sold to state hospitals at or above its list price of at least $3,000 per box, after 95% of state tenders between 2020 and 2023 drew a single participant. Distributor Pharmimex won $114.3 million of nearly $129 million in state contracts for another drug, Koselugo, between 2022 and 2024 without competition.
Swiss pharmaceutical group Novartis was alleged to have identified examples of bid-rigging in government auctions for the drug Kisqali. A company representative said an internal investigation was carried out but did not disclose its findings. AstraZeneca, Merck and Eli Lilly declined to comment or did not respond.
Legal context
The whistleblower reports contain no direct records of bank transfers between distributors and officials, but allege that the drugmakers were "willfully blind" to how their margins were used. The U.S. Foreign Corrupt Practices Act holds parent companies liable for ignoring signs that third-party distributors use margins to fund kickbacks. The U.S. Securities and Exchange Commission and the Justice Department declined to comment on the filings.
